Антиаритмический препарат пропафенон: место в клинической практике (обзор)
Антиаритмический препарат пропафенон: место в клинической практике (обзор)
Сыров А.В., Павлова Т.В. Антиаритмический препарат пропафенон: место в клинической практике (обзор). Consilium Medicum. 2019; 21 (12): 112–117. DOI: 10.26442/20751753.2019.12.190724
________________________________________________
Syrov A.V., Pavlova T.V. Antiarrhythmic medication propafenone: place in clinical practice (review). Consilium Medicum. 2019; 21 (12): 112–117. DOI: 10.26442/20751753.2019.12.190724
Антиаритмический препарат пропафенон: место в клинической практике (обзор)
Сыров А.В., Павлова Т.В. Антиаритмический препарат пропафенон: место в клинической практике (обзор). Consilium Medicum. 2019; 21 (12): 112–117. DOI: 10.26442/20751753.2019.12.190724
________________________________________________
Syrov A.V., Pavlova T.V. Antiarrhythmic medication propafenone: place in clinical practice (review). Consilium Medicum. 2019; 21 (12): 112–117. DOI: 10.26442/20751753.2019.12.190724
В настоящее время антиаритмические препараты широко применяются в клинической практике, влияя на клинические проявления аритмий, что позволяет существенно повысить качество жизни пациентов. Ключевым вопросом при проведении антиаритмической терапии является обеспечение безопасности лечения. Пропафенон выделяется среди всех антиаритмических препаратов наличием большой доказательной базы, полученной в разных группах пациентов, эффективностью и безопасностью, а также доступностью как пероральной, так и внутривенной форм введения. У пациентов без выраженного органического поражения сердца пропафенон – препарат выбора в большом числе клинических ситуаций: экстрасистолии, наджелудочковой тахикардии, фибрилляции предсердий и трепетании предсердий и даже отдельных видах желудочковой тахикардии.
Currently, antiarrhythmic drugs are widely used in clinical practice, influencing the clinical manifestations of arrhythmias, which can significantly improve the quality of life of patients. A key issue in antiarrhythmic therapy is ensuring the safety of treatment. Propafenone stands out among all antiarrhythmic drugs by the presence of a large evidence base obtained in various groups of patients, efficacy and safety, as well as the availability of both oral and intravenous forms of administration. In patients without a pronounced organic lesion of the heart, propafenone is the drug of choice in a large number of clinical situations: extrasystole, supraventricular tachycardia, atrial fibrillation and atrial flutter, and even certain types of ventricular tachycardia.
1. Zulkifly H, Lip G, Lane D. Epidemiology of atrial fibrillation. Int J Clin Pract 2018; 72 (3): 13070. DOI: 10.1111/ijcp.13070
2. Pistoia F, Sacco S, Tiseo C et al. The epidemiology of atrial fibrillation and stroke. Cardiol Clin 2016; 34 (2): 255–68.
3. Наджелудочковые нарушения сердечного ритма у взрослых. Клинические рекомендации. Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и электростимуляции, Общество специалистов по неотложной кардиологии. 2016 г.
[Nadzheludochkovye narusheniia serdechnogo ritma u vzroslykh. Klinicheskie rekomendatsii. Vserossiiskoe nauchnoe obshchestvo spetsialistov po klinicheskoi elektrofiziologii, aritmologii i elektrostimuliatsii, Obshchestvo spetsialistov po neotlozhnoi kardiologii. 2016 g. (in Russian).]
4. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
5. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC).
6. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации. Всероссийского научного общества специалистов по клинической электрофизиологии, Аритмологии и электрокардиостимуляции (ВНОА) в сотрудничестве с Российским кардиологическим обществом (РКО) и Ассоциации сердечно‐сосудистых хирургов России (АССХ). 2017 г.
[Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii. Vserossiiskogo nauchnogo obshchestva spetsialistov po klinicheskoi elektrofiziologii, Aritmologii i elektrokardiostimuliatsii (VNOA) v sotrudnichestve s Rossiiskim kardiologicheskim obshchestvom (RKO) i Assotsiatsii serdechno‐sosudistykh khirurgov Rossii (ASSKh). 2017 g. (in Russian).]
7. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients with Supraventricular Tachycardia. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
8. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
9. RXlist amiodarone.
10. RXlist sotalol.
11. RXlist propaphenone.
12. Фомина И.Г., Тарзиманова А.И., Вертлужский А.В. и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий.
«ПРОМЕТЕЙ» – открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2005; 4 (4): 66–9.
[Fomina I.G., Tarzimanova A.I., Vertluzhskii A.V. et al. Propafenon pri vosstanovlenii sinusovogo ritma u bol'nykh s persistiruiushchei formoi fibrilliatsii predserdii. "PROMETEI" – otkrytoe, mul'titsentrovoe, pilotnoe issledovanie v Rossiiskoi Federatsii. Kardiovaskuliarnaia terapiia i profilaktika. 2005; 4 (4): 66–9 (in Russian).]
13. André Ng G. Treating patients with ventricular ectopic beats. Heart 2006; 92 (11): 1707–12.
14. Kennedy HL, Whitlock JA, Sprague MK et al. Long‐term follow‐up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985; 312 (4): 193–7.
15. Kostis J. The prognostic significance of ventricular ectopic activity. Am J Cardiol 1992; 70: 807–8.
16. Kostis J, McCrone K, Moreyra AE et al Premature ventricular complexes in the absence of identifiable heart disease. Circulation 1981; 63: 1351–6.
17. Morshedi‐Meibodi A, Evans JC, Levy D et al. Clinical correlates and prognostic significance of exercise‐induced ventricular premature beats in the community: the Framingham Heart Study. Circulation 2004; 109 (20): 2417–22.
18. Niwano S, Wakisaka Y, Niwano H et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart 2009; 95: 1230–7.
19. Jouven X, Zureik M, Desnos M et al. Long‐term outcome in asymptomatic men with exercise‐induced premature ventricular depolarizations. N Engl J Med 2000; 34 (3): 826–33.
20. DeBacker G, Jacobs D, Prineas R et al. Ventricular premature contractions: a randomized non-drug intervention trial in normal men. Circulation 1979; 59: 762–9.
21. Glatter KA, Myers R, Chiamvimonvat N. Recommendations regarding dietary intake and caffeine and alcohol consumption in patients with cardiac arrhythmias: what do you tell your patients to do or not to do? Curr Treat Options Cardiovasc Med 2012; 14: 529–35.
22. Myers MG. Caffeine and cardiac arrhythmias. Ann Intern Med 1991; 114 (2): 147–50.
23. Al-Khatib S, Allen LaPointe N, Chatterjee R et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014; 160 (11): 760–73.
24. Carlsson J, Miketic S, Windeler J et al. STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41 (10): 1690–6.
25. Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE 2013; 36 (1): 122–33.
26. Hohnloser S, Kuck K, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356 (9244): 1789–94.
27. Olshansky B, Rosenfeld LE, Warner AL et al. AFFIRM Investigators The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43 (7): 1201–8.
28. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667–77.
29. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012; 105 (4): 226–38.
30. Sethi N, Safi S, Nielsen E et al. The effects of rhythm control strategiesversus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. System Rev 2017; 6: 47. DOI 10.1186/s13643-017-0449-z
31. Van Gelder I, Hagens V, Kingma J et al. Rate control versus electrical cardioversion for atrial fibrillation. A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit – the RACE study design. Neth Heart J 2002; 10 (3): 118–4.
32. Оганов Р.Г., Симаненков В.И., Бакулин И.Г., Сыров А.В. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2019; 1: 5–66.
[Oganov R.G., Simanenkov V.I., Bakulin I.G., Syrov A.V. Komorbidnaia patologiia v klinicheskoi praktike. Algoritmy diagnostiki i lecheniia. Klinicheskie rekomendatsii. Kardiovaskuliarnaia terapiia i profilaktika. 2019; 1: 5–66 (in Russian).]
33. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004; 351 (23): 2384–91.
34. Meinertz T, Lip GY, Lombardi F et al. ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002; 90 (12): 1300–6.
35. Porterfield J, Porterfield L.Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol 1989; 63 (1): 114–6. Am J Cardiol 2004; 94 (5): 663–5.
36. Antonelli D, Darawsha A, Rimbrot S et al. Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation. Harefuah 1999; 136 (11): 857–9.
37. Azpitarte J, Alvarez M, Baún O et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997; 18 (10): 1649–54.
38. Boriani G, Biffi M, Capucci A et al. Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol 1998; 21 (11 Pt 2): 2465–9.
39. Boriani G, Martignani C, Biffi M et al. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs 2002; 62 (3): 415 23.
40. Blanc J, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999; 84 (9): 1029–32.
41. Botto G, Capucci A, Bonini W et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol 1997; 58 (1): 55–61.
42. Capucci A, Villani GQ, Aschieri D, Piepoli M. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int J Cardiol 1999; 68 (2): 187–96. Erratum in: Int J Cardiol 1999; 70 (2): 213.
43. Martignani C, Diemberger I, Ziacchi M et al. Oral loading of propafenone: restoring its role before restoring rhythm. Europace 2017; 19 (11): 1903.
44. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37 (2): 542–7.
45. Hughes C, Sunderji R, Gin K. Oral propafenone for rapid conversion of recent onset atrial fibrillation – a review. Can J Cardiol 1997; 13 (9): 839–42.
46. Antonelli D, Freedberg NA, Feldman A et al. Intravenous propafenone for conversion of atrial fibrillation in the emergency room. Harefuah 2004; 143 (7): 471–4.
47. Boriani G, Capucci A, Lenzi T et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995; 108 (2): 355–8.
48. Capucci A, Boriani G. Intravenous administration of propafenone. J Am Coll Cardiol 1992; 19 (6): 1368–9.
49. Cointe R, Metge M, Bru P, et al. Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation. Ann Cardiol Angeiol (Paris) 1993; 42 (4): 223–7.
50. Carerj S, Cavalli G, Magazù A et al. Treatment of recent atrial fibrillation with intravenous propafenone. Cardiologia 1989; 34 (1): 83–5.
51. Goy J, Métrailler J, Humair L, de Torrenté A. Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J 1991; 122 (6): 1788–90.
52. Haefeli EW, Vozeh S, Ha HR, Follath F. Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 1990; 48 (3): 245–54.
53. Liguori A, di Ieso N, D'Armiento F et al. Intravenous propafenone for suppression of symptomatic atrial fibrillation and atrial flutter in a first aid hospital. Riv Eur Sci Med Farmacol 1992; 14 (4):
229–32.
54. Madonia S, De Simone M, Brai G et al. Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial. Ital Heart
J 2000; 1 (7): 475–9.
55. Margheri M, Fradella G, Maioli M et al. Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation. G Ital Cardiol 1992; 22 (3): 257–65.
56. Velázquez Rodríguez E, Cancino Rodríguez C, Arias Estrada S,et al. Pharmacological cardioversion with intravenous propafenone in atrial fibrillation. Arch Inst Cardiol Mex 2000; 70 (2): 160–6.
57. Zadura M, Grossmann G, Modrzewska A et al. Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation. Pol Merkur Lekarski 2001; 11 (62): 137–9.
58. Antman EM, Beamer AD, Cantillon C et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12 (4): 1005–11.
59. Kowey PR, Yannicelli D, Amsterdam E; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2004;
94 (5): 663–5.
60. Лукьянова И.Ю., Кузнецов А.В., Комарницкий В.М., Козырева А.Г. Изучение эффективности и безопасности препаратов для медикаментозной кардиоверсии у больных с пароксизмальной формой фибрилляции предсердий на догоспитальном этапе. Скорая медицинская помощь. 2017; 4: 43–7.
[Luk'ianova I.Iu., Kuznetsov A.V., Komarnitskii V.M., Kozyreva A.G. Izuchenie effektivnosti i bezopasnosti preparatov dlia medikamentoznoi kardioversii u bol'nykh s paroksizmal'noi formoi fibrilliatsii predserdii na dogospital'nom etape. Skoraia meditsinskaia pomoshch'. 2017; 4: 43–7
(in Russian).]
61. Миллер О.Н., Старичков С.А., Поздняков и др. Эффективность и безопасность применения пропафенона (пропанорма®) и амиодарона (кордарона®) у больных с фибрилляцией предсердий на фоне АГ, ИБС и ХСН с сохраненной систолической функцией ЛЖ. Многоцентровое открытое рандомизированное, проспективное, сравнительное исследование ПРОСТОР. Рос. кардиологический журн. 2010; 4: 56–72.
[iller O.N., Starichkov S.A., Pozdniakov et al. Effektivnost' i bezopasnost' primeneniia propafenona (propanorma®) i amiodarona (kordarona®) u bol'nykh s fibrilliatsiei predserdii na fone AG, IBS i KhSN s sokhranennoi sistolicheskoi funktsiei LZh. Mnogotsentrovoe otkrytoe randomizirovannoe, prospektivnoe, sravnitel'noe issledovanie PROSTOR. Ros. kardiologicheskii zhurn. 2010; 4:
56–72 (in Russian).]
62. Тарасов А.В., Косых С.А., Бушуева Е.В. и др. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019; 1: 81–6.
[Tarasov A.V., Kosykh S.A., Bushueva E.V. et al. Comparison of antiarrhythmic medications propafenone and amiodarone injection forms effectiveness in medicamentous cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019; 21 (1): 81–6 (in Russian).]
63. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann J, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; 5: CD005049.
64. Клинические рекомендации «Желудочковые аритмии». ФГБУ «ННПЦССХ им. А.Н.Бакулева». Центр хирургической и интервенционной аритмологии. М., 2017.
[Clinical recommendations "Ventricular arrhythmias". Bakulev National Medical Research Center for Cardiovascular Surgery. Center for Surgical and Interventional Arrhythmology. Moscow, 2017 (in Russian).]
65. Клинические рекомендации по диагностике и лечению нарушений ритма сердца и проводимости. Общество специалистов по неотложной кардиологии, 2013.
[Klinicheskie rekomendatsii po diagnostike i lecheniiu narushenii ritma serdtsa i provodimosti. Obshchestvo spetsialistov po neotlozhnoi kardiologii, 2013 (in Russian).]
66. Iwai S, Lerman BB. Management of ventricular tachycardia in patients with clinically normal hearts. Curr Cardiol Rep 2000; 2: 515–21.
67. Bigger JT Jr, Dresdale FJ, Heissenbuttel RH et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977; 19: 255–300.
68. Eldar M, Sievner Z, Goldbourt U et al. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. The SPRINT Study Group. Ann Intern Med 1992; 117: 31–6.
69. Ng E, Adlam D, Keal RP et al. Recurrent ventricular tachycardia of non‐ischaemic origin. J Royal Soc Med 2004; 97 (1): 23–5.
70. Bardy G, Lee K, Mark D et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (3): 225–37.
________________________________________________
1. Zulkifly H, Lip G, Lane D. Epidemiology of atrial fibrillation. Int J Clin Pract 2018; 72 (3): 13070. DOI: 10.1111/ijcp.13070
2. Pistoia F, Sacco S, Tiseo C et al. The epidemiology of atrial fibrillation and stroke. Cardiol Clin 2016; 34 (2): 255–68.
3. Nadzheludochkovye narusheniia serdechnogo ritma u vzroslykh. Klinicheskie rekomendatsii. Vserossiiskoe nauchnoe obshchestvo spetsialistov po klinicheskoi elektrofiziologii, aritmologii i elektrostimuliatsii, Obshchestvo spetsialistov po neotlozhnoi kardiologii. 2016 g. (in Russian).
4. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
5. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC).
6. Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii. Vserossiiskogo nauchnogo obshchestva spetsialistov po klinicheskoi elektrofiziologii, Aritmologii i elektrokardiostimuliatsii (VNOA) v sotrudnichestve s Rossiiskim kardiologicheskim obshchestvom (RKO) i Assotsiatsii serdechno‐sosudistykh khirurgov Rossii (ASSKh). 2017 g. (in Russian).
7. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients with Supraventricular Tachycardia. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
8. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
9. RXlist amiodarone.
10. RXlist sotalol.
11. RXlist propaphenone.
12. Fomina I.G., Tarzimanova A.I., Vertluzhskii A.V. et al. Propafenon pri vosstanovlenii sinusovogo ritma u bol'nykh s persistiruiushchei formoi fibrilliatsii predserdii. "PROMETEI" – otkrytoe, mul'titsentrovoe, pilotnoe issledovanie v Rossiiskoi Federatsii. Kardiovaskuliarnaia terapiia i profilaktika. 2005; 4 (4): 66–9 (in Russian).
13. André Ng G. Treating patients with ventricular ectopic beats. Heart 2006; 92 (11): 1707–12.
14. Kennedy HL, Whitlock JA, Sprague MK et al. Long‐term follow‐up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985; 312 (4): 193–7.
15. Kostis J. The prognostic significance of ventricular ectopic activity. Am J Cardiol 1992; 70: 807–8.
16. Kostis J, McCrone K, Moreyra AE et al Premature ventricular complexes in the absence of identifiable heart disease. Circulation 1981; 63: 1351–6.
17. Morshedi‐Meibodi A, Evans JC, Levy D et al. Clinical correlates and prognostic significance of exercise‐induced ventricular premature beats in the community: the Framingham Heart Study. Circulation 2004; 109 (20): 2417–22.
18. Niwano S, Wakisaka Y, Niwano H et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart 2009; 95: 1230–7.
19. Jouven X, Zureik M, Desnos M et al. Long‐term outcome in asymptomatic men with exercise‐induced premature ventricular depolarizations. N Engl J Med 2000; 34 (3): 826–33.
20. DeBacker G, Jacobs D, Prineas R et al. Ventricular premature contractions: a randomized non-drug intervention trial in normal men. Circulation 1979; 59: 762–9.
21. Glatter KA, Myers R, Chiamvimonvat N. Recommendations regarding dietary intake and caffeine and alcohol consumption in patients with cardiac arrhythmias: what do you tell your patients to do or not to do? Curr Treat Options Cardiovasc Med 2012; 14: 529–35.
22. Myers MG. Caffeine and cardiac arrhythmias. Ann Intern Med 1991; 114 (2): 147–50.
23. Al-Khatib S, Allen LaPointe N, Chatterjee R et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014; 160 (11): 760–73.
24. Carlsson J, Miketic S, Windeler J et al. STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41 (10): 1690–6.
25. Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE 2013; 36 (1): 122–33.
26. Hohnloser S, Kuck K, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356 (9244): 1789–94.
27. Olshansky B, Rosenfeld LE, Warner AL et al. AFFIRM Investigators The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43 (7): 1201–8.
28. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667–77.
29. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012; 105 (4): 226–38.
30. Sethi N, Safi S, Nielsen E et al. The effects of rhythm control strategiesversus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. System Rev 2017; 6: 47. DOI 10.1186/s13643-017-0449-z
31. Van Gelder I, Hagens V, Kingma J et al. Rate control versus electrical cardioversion for atrial fibrillation. A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit – the RACE study design. Neth Heart J 2002; 10 (3): 118–4.
32. Oganov R.G., Simanenkov V.I., Bakulin I.G., Syrov A.V. Komorbidnaia patologiia v klinicheskoi praktike. Algoritmy diagnostiki i lecheniia. Klinicheskie rekomendatsii. Kardiovaskuliarnaia terapiia i profilaktika. 2019; 1: 5–66 (in Russian).
33. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004; 351 (23): 2384–91.
34. Meinertz T, Lip GY, Lombardi F et al. ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002; 90 (12): 1300–6.
35. Porterfield J, Porterfield L.Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol 1989; 63 (1): 114–6. Am J Cardiol 2004; 94 (5): 663–5.
36. Antonelli D, Darawsha A, Rimbrot S et al. Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation. Harefuah 1999; 136 (11): 857–9.
37. Azpitarte J, Alvarez M, Baún O et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997; 18 (10): 1649–54.
38. Boriani G, Biffi M, Capucci A et al. Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol 1998; 21 (11 Pt 2): 2465–9.
39. Boriani G, Martignani C, Biffi M et al. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs 2002; 62 (3): 415 23.
40. Blanc J, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999; 84 (9): 1029–32.
41. Botto G, Capucci A, Bonini W et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol 1997; 58 (1): 55–61.
42. Capucci A, Villani GQ, Aschieri D, Piepoli M. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int J Cardiol 1999; 68 (2): 187–96. Erratum in: Int J Cardiol 1999; 70 (2): 213.
43. Martignani C, Diemberger I, Ziacchi M et al. Oral loading of propafenone: restoring its role before restoring rhythm. Europace 2017; 19 (11): 1903.
44. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37 (2): 542–7.
45. Hughes C, Sunderji R, Gin K. Oral propafenone for rapid conversion of recent onset atrial fibrillation – a review. Can J Cardiol 1997; 13 (9): 839–42.
46. Antonelli D, Freedberg NA, Feldman A et al. Intravenous propafenone for conversion of atrial fibrillation in the emergency room. Harefuah 2004; 143 (7): 471–4.
47. Boriani G, Capucci A, Lenzi T et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995; 108 (2): 355–8.
48. Capucci A, Boriani G. Intravenous administration of propafenone. J Am Coll Cardiol 1992; 19 (6): 1368–9.
49. Cointe R, Metge M, Bru P, et al. Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation. Ann Cardiol Angeiol (Paris) 1993; 42 (4): 223–7.
50. Carerj S, Cavalli G, Magazù A et al. Treatment of recent atrial fibrillation with intravenous propafenone. Cardiologia 1989; 34 (1): 83–5.
51. Goy J, Métrailler J, Humair L, de Torrenté A. Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J 1991; 122 (6): 1788–90.
52. Haefeli EW, Vozeh S, Ha HR, Follath F. Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 1990; 48 (3): 245–54.
53. Liguori A, di Ieso N, D'Armiento F et al. Intravenous propafenone for suppression of symptomatic atrial fibrillation and atrial flutter in a first aid hospital. Riv Eur Sci Med Farmacol 1992; 14 (4):
229–32.
54. Madonia S, De Simone M, Brai G et al. Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial. Ital Heart
J 2000; 1 (7): 475–9.
55. Margheri M, Fradella G, Maioli M et al. Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation. G Ital Cardiol 1992; 22 (3): 257–65.
56. Velázquez Rodríguez E, Cancino Rodríguez C, Arias Estrada S,et al. Pharmacological cardioversion with intravenous propafenone in atrial fibrillation. Arch Inst Cardiol Mex 2000; 70 (2): 160–6.
57. Zadura M, Grossmann G, Modrzewska A et al. Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation. Pol Merkur Lekarski 2001; 11 (62): 137–9.
58. Antman EM, Beamer AD, Cantillon C et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12 (4): 1005–11.
59. Kowey PR, Yannicelli D, Amsterdam E; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2004;
94 (5): 663–5.
60. Luk'ianova I.Iu., Kuznetsov A.V., Komarnitskii V.M., Kozyreva A.G. Izuchenie effektivnosti i bezopasnosti preparatov dlia medikamentoznoi kardioversii u bol'nykh s paroksizmal'noi formoi fibrilliatsii predserdii na dogospital'nom etape. Skoraia meditsinskaia pomoshch'. 2017; 4: 43–7 (in Russian)
61. Miller O.N., Starichkov S.A., Pozdniakov et al. Effektivnost' i bezopasnost' primeneniia propafenona (propanorma®) i amiodarona (kordarona®) u bol'nykh s fibrilliatsiei predserdii na fone AG, IBS i KhSN s sokhranennoi sistolicheskoi funktsiei LZh. Mnogotsentrovoe otkrytoe randomizirovannoe, prospektivnoe, sravnitel'noe issledovanie PROSTOR. Ros. kardiologicheskii zhurn. 2010; 4:
56–72 (in Russian).
62. Tarasov A.V., Kosykh S.A., Bushueva E.V. et al. Comparison of antiarrhythmic medications propafenone and amiodarone injection forms effectiveness in medicamentous cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019; 21 (1): 81–6 (in Russian).
63. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann J, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; 5: CD005049.
64. Clinical recommendations "Ventricular arrhythmias". Bakulev National Medical Research Center for Cardiovascular Surgery. Center for Surgical and Interventional Arrhythmology. Moscow, 2017 (in Russian).
65. Klinicheskie rekomendatsii po diagnostike i lecheniiu narushenii ritma serdtsa i provodimosti. Obshchestvo spetsialistov po neotlozhnoi kardiologii, 2013 (in Russian).
66. Iwai S, Lerman BB. Management of ventricular tachycardia in patients with clinically normal hearts. Curr Cardiol Rep 2000; 2: 515–21.
67. Bigger JT Jr, Dresdale FJ, Heissenbuttel RH et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977; 19: 255–300.
68. Eldar M, Sievner Z, Goldbourt U et al. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. The SPRINT Study Group. Ann Intern Med 1992; 117: 31–6.
69. Ng E, Adlam D, Keal RP et al. Recurrent ventricular tachycardia of non‐ischaemic origin. J Royal Soc Med 2004; 97 (1): 23–5.
70. Bardy G, Lee K, Mark D et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (3): 225–37.
Авторы
А.В. Сыров*1,2, Т.В. Павлова3,4
1 ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия;
2 ГБУЗ «Консультативно-диагностический центр №6» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, Самара, Россия;
4 ГБУЗ «Самарский областной клинический кардиологический диспансер», Самара, Россия
*syrman2002_1@yahoo.com
________________________________________________
Andrei V. Syrov*1,2, Tatiana V. Pavlova3,4
1 People’s Friendship University of Russia, Moscow, Russia;
2 Consultative and Diagnostic Center №6, Moscow, Russia;
3 Samara State Medical University, Samara, Russia;
4 Samara Regional Clinical Cardiology Dispensary, Samara, Russia
*syrman2002_1@yahoo.com